Indaptus Therapeutics, Inc.
INDP
$2.16
$0.168.00%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.13M | 2.29M | 1.76M | 1.69M | 1.68M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.65M | 4.46M | 4.57M | 4.17M | 3.14M |
| Operating Income | -2.65M | -4.46M | -4.57M | -4.17M | -3.14M |
| Income Before Tax | -2.98M | -5.23M | -4.53M | -4.13M | -3.07M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.98M | -5.23M | -4.53M | -4.13M | -3.07M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.98M | -5.23M | -4.53M | -4.13M | -3.07M |
| EBIT | -2.65M | -4.46M | -4.57M | -4.17M | -3.14M |
| EBITDA | -2.65M | -4.46M | -4.57M | -4.17M | -3.14M |
| EPS Basic | -2.98 | -9.10 | -9.00 | -10.59 | -9.04 |
| Normalized Basic EPS | -1.87 | -5.68 | -5.62 | -6.62 | -5.65 |
| EPS Diluted | -2.98 | -9.10 | -9.00 | -10.59 | -9.04 |
| Normalized Diluted EPS | -1.87 | -5.68 | -5.62 | -6.62 | -5.65 |
| Average Basic Shares Outstanding | 997.00K | 574.90K | 503.70K | 390.20K | 339.70K |
| Average Diluted Shares Outstanding | 997.00K | 574.90K | 503.70K | 390.20K | 339.70K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |